【环球网财经综合报道】国家流感中心发布的中国流感监测周报显示，2025年11月24日至11月30日，我 国流感活动继续上升；并预测今年秋冬流感高峰可能出现在12月中下旬至明年1月初，市场对抗病毒药 物及对症治疗药物的需求大幅增长，特别是儿童作为流感易感人群，用药需求尤为迫切。 凭借在儿童医药领域的深耕优势，海南葫芦娃药业集团股份有限公司旗下的磷酸奥司他韦系列产品表现 亮眼。公开数据显示，葫芦娃药业的磷酸奥司他韦胶囊剂已获批生产并稳定供应市场，适用于甲型、乙 型流感的预防与治疗；公司研发的干混悬剂于今年9月获得药品注册证书，满足2周岁及以上低龄患儿的 用药需求，有效解决了低龄儿童服用抗流感药物"剂量难把控"的问题。 在中成药领域，公司的核心产品小儿肺热咳喘颗粒则已连续多年入选国家卫健委《流行性感冒诊疗方 案》，并已纳入国家医保目录，被全国多省市纳入地方流感诊疗指南。此外，公司生产的复方氨酚烷胺 胶囊、布洛芬混悬滴剂、乙酰半胱氨酸溶液，则有助于缓解普通感冒及流行性感冒引发的发热、头痛等 症状。 根据此前发布的三季报及半年报数据显示，公司现有341个药品批文，7款1类创新药、9款2类新药处于 不同研发阶段，其中3款 ...

Core Viewpoint - West Point Pharmaceutical (301130.SZ) has announced its existing products, including a mature anti-influenza drug, compound acetaminophen and amantadine capsules, and an antiviral tablet expected to be approved for market in 2025 for treating upper respiratory infections and influenza [1] Group 1 - The company has a mature anti-influenza product, compound acetaminophen and amantadine capsules [1] - An antiviral tablet is anticipated to receive approval for market launch in 2025, aimed at treating upper respiratory infections and influenza [1] - The research project on "the intervention effect of Ruixiangsu on mouse models of human diseases" has shown safety and efficacy results for Ruixiangsu in treating viral pneumonia [1] Group 2 - The company has obtained a patent for "the application of Ruixiangsu in the preparation of drugs for treating viral pneumonia" [1]

Core Viewpoint - The company, Renhe Pharmaceutical, confirmed the availability of several influenza treatment medications and emphasized its commitment to ensuring stable production and supply to meet market demand [2]. Product Information - The company currently sells influenza treatment medications including Oseltamivir Phosphate Capsules, Ibuprofen Sustained-Release Capsules, Amoxicillin Capsules, Compound Aminophenol and Amantadine Capsules, Strong Loquat Capsules, and Pediatric Acetaminophen Granules [2]. - In addition to these, the company offers various medications for symptoms related to influenza-like illnesses, providing consumers with multiple options for symptomatic relief [2]. Supply Assurance - The company has prioritized the supply of these influenza-related medications to ensure they meet market demand effectively [2].

Core Viewpoint - The company has existing flu medication products and is developing new antiviral treatments, indicating a strong position in the respiratory infection market [2]. Product Overview - The company currently markets a mature flu medication, Compound Acetaminophen and Amantadine Capsules [2]. - An antiviral tablet is expected to receive approval for market launch in 2025, aimed at treating upper respiratory infections and influenza [2]. Research and Development - The company is conducting research on "Rui Xiang Su" for its effects on viral pneumonia in mouse models, showing safety and efficacy [2]. - A patent has been obtained for the application of "Rui Xiang Su" in the preparation of drugs for treating viral pneumonia [2]. - The company is the sole producer and seller of "Rui Xiang Su" capsules in China [2].